Breast cancer drug rejected for NHS use on cost-benefit grounds
Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine months on average
A breast cancer drug that costs £90,000 a year per patient has been turned down for use by the NHS on financial grounds, triggering an outcry from patients groups who say it prolongs the lives of people seriously ill with the disease.
Kadcyla, made by Roche Pharmaceuticals, was rejected by the National Institute for Health and Care Excellence. It has the highest price tag ever for a cancer medicine and was turned down because its benefits did not justify its cost, Nice said.
More From Around the Web
Check out these Articles
- Abbvie withdraws bid for Shire after US gets tough on tax
- Co-op Group to sell farms business and consider offloading pharmacy chain
- GSK and Lundbeck Present on Improving Drug-Drug Interaction at ADMET 2016
- As battle over AstraZeneca looms, one lab in Slough shows mergers can work
- Healthy Lifestyles LLC Announces Prostatection™ All-Natural Prostate Heal...
- The European court of human rights judgments that transformed British law
- Deadline Extended for Submitting Public Comment on FDA’s Compounding Anim...
- Is the failure of health regulation damaging our well-being? | Aseem Malhot...
- Seaweed: marine life coming ashore
- Pfizer’s initial offer for AstraZeneca is plainly dead in the water |...
- Rotapharm and Repretin | Letters
- China confirms trial of GSK foreign investigators
- GSK is in good health, so no need for new CEO to start looking for medicine
- Thalidomide the 50 Year Fight; Tyger Takes on Porn TV review